In post-Roe US, clinical trials may be too risky during pregnancy

In an op-ed last year in Stat, Aoife Brennan, the CEO of a Massachusetts-based company developing treatments for metabolic and immune-based diseases, described the situation of a 32-year-old woman who was participating in a Phase 1 trial. She tested negative for pregnancy at enrollment and agreed to use contraception. Still, when she checked in for … Read more